Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study

NCT02818725 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02818725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02818725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2010
Completion date
September 30, 2017
Enrollment
133 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

infiltrating urothelial carcinoma, kras gene mutation